204 related articles for article (PubMed ID: 16284340)
21. On the prognostic value of survival models with application to gene expression signatures.
Hielscher T; Zucknick M; Werft W; Benner A
Stat Med; 2010 Mar; 29(7-8):818-29. PubMed ID: 20213714
[TBL] [Abstract][Full Text] [Related]
22. Boosting method for nonlinear transformation models with censored survival data.
Lu W; Li L
Biostatistics; 2008 Oct; 9(4):658-67. PubMed ID: 18344565
[TBL] [Abstract][Full Text] [Related]
23. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
[TBL] [Abstract][Full Text] [Related]
24. Prognostic biomarkers in diffuse large B-cell lymphoma.
Lossos IS; Morgensztern D
J Clin Oncol; 2006 Feb; 24(6):995-1007. PubMed ID: 16418498
[TBL] [Abstract][Full Text] [Related]
25. Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas.
Mircean C; Tabus I; Kobayashi T; Yamaguchi M; Shiku H; Shmulevich I; Zhang W
Int J Oncol; 2004 Mar; 24(3):497-504. PubMed ID: 14767533
[TBL] [Abstract][Full Text] [Related]
26. Logical analysis of diffuse large B-cell lymphomas.
Alexe G; Alexe S; Axelrod DE; Hammer PL; Weissmann D
Artif Intell Med; 2005 Jul; 34(3):235-67. PubMed ID: 16023562
[TBL] [Abstract][Full Text] [Related]
27. Analysis of additive risk model with high-dimensional covariates using partial least squares.
Zhao Y; Zhou Y; Zhao M
Stat Med; 2009 Jan; 28(2):181-93. PubMed ID: 18800330
[TBL] [Abstract][Full Text] [Related]
28. Partial least squares dimension reduction for microarray gene expression data with a censored response.
Nguyen DV
Math Biosci; 2005 Jan; 193(1):119-37. PubMed ID: 15681279
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic value of gene expression profiling using cDNA arrays in lymphomas].
Bertucci F; Salas S; Nasser V; Houlgatte R; Birnbaum D; Xerri L
Bull Cancer; 2002; 89(7-8):661-5. PubMed ID: 12206978
[TBL] [Abstract][Full Text] [Related]
30. Assessment of evaluation criteria for survival prediction from genomic data.
Bøvelstad HM; Borgan O
Biom J; 2011 Mar; 53(2):202-16. PubMed ID: 21308723
[TBL] [Abstract][Full Text] [Related]
31. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
[TBL] [Abstract][Full Text] [Related]
32. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (GI) tract are blastic variants of GI marginal zone lymphoma.
Barth TF; Barth CA; Kestler HA; Michl P; Weniger MA; Buchholz M; Möller P; Gress T
J Pathol; 2007 Feb; 211(3):305-13. PubMed ID: 17152084
[TBL] [Abstract][Full Text] [Related]
34. Molecular characteristics of diffuse large-B-cell lymphoma.
Magrath I
N Engl J Med; 2002 Jun; 346(25):1998-9. PubMed ID: 12075062
[No Abstract] [Full Text] [Related]
35. Recent advances in the molecular diagnosis of diffuse large B-cell lymphoma.
Fu K; Iqbal J; Chan WC
Expert Rev Mol Diagn; 2005 May; 5(3):397-408. PubMed ID: 15934816
[TBL] [Abstract][Full Text] [Related]
36. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
[TBL] [Abstract][Full Text] [Related]
37. [Gene expression profiling of de novo CD5-positive diffuse large B-cell lymphoma].
Kobayashi T; Kim S; Zhang W; Yamaguchi M; Ueno S; Morikawa J; Shiku H
Rinsho Ketsueki; 2003 Mar; 44(3):144-8. PubMed ID: 12722340
[No Abstract] [Full Text] [Related]
38. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G
J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351
[TBL] [Abstract][Full Text] [Related]
40. Drug resistance in diffuse large B-cell lymphoma.
Wilson WH
Semin Hematol; 2006 Oct; 43(4):230-9. PubMed ID: 17027657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
